Junrong Wang

Nov 28, 2024 | onlinelibrary.wiley.com | Songbin Liu |Shan Yang |Junrong Wang |Zhengce An

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description lpor202401652-sup-0001-SuppMat.docx4.5 MB Supporting Information References 1, , , , , , , Chem. Rev. 2022, 122, 15998. 2, , , , , Chem. Soc. Rev. 2022, 51, 1729. 3, , , , , , , J. Mater. Chem. A 2021, 9, 4007. 4, , , , Nat. Nanotechnol. 2015, 10, 924. 5, , Prog. Nat. Sci.: Mater. Int. 2022, 32, 674. 6, , , , , Nano Lett. 2022, 22, 7042. 7, , , , , Mater. Horiz.

Oct 27, 2024 | onlinelibrary.wiley.com | Wei Lai |Zhou Ping |Yun Chen |Junrong Wang

1 INTRODUCTION To date, targeted therapy has become one of the preferred methods for treating most cancers.1 However, resistance often occurs during targeted therapy.2 This may be due to the emergence of resistant mutations, compensatory activation of alternative signalling pathways, or the preexistence of cells with dominant growth-carrying resistance gene alterations.